IQVIA (NYSE:IQV) Upgraded by Wall Street Zen to Buy Rating

Wall Street Zen upgraded shares of IQVIA (NYSE:IQV) from a hold rating to a buy rating in a research report sent to investors on Sunday.

Several other equities analysts also recently weighed in on the stock. Morgan Stanley raised their target price on shares of IQVIA from $250.00 to $265.00 and gave the company an “overweight” rating in a report on Monday, December 1st. Hsbc Global Res raised shares of IQVIA from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 9th. UBS Group upped their target price on IQVIA from $250.00 to $280.00 and gave the company a “buy” rating in a research note on Thursday, January 8th. Robert W. Baird set a $258.00 target price on IQVIA and gave the company an “outperform” rating in a report on Wednesday, October 29th. Finally, Stifel Nicolaus boosted their price target on IQVIA from $234.00 to $254.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $251.06.

IQVIA Stock Performance

IQV opened at $235.20 on Friday. The stock’s 50 day simple moving average is $229.10 and its 200 day simple moving average is $206.21. The stock has a market cap of $40.05 billion, a P/E ratio of 32.26, a P/E/G ratio of 2.39 and a beta of 1.36. IQVIA has a 1-year low of $134.65 and a 1-year high of $247.04. The company has a debt-to-equity ratio of 2.03, a current ratio of 0.70 and a quick ratio of 0.70.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, October 28th. The medical research company reported $3.00 EPS for the quarter, topping analysts’ consensus estimates of $2.98 by $0.02. The company had revenue of $4.10 billion for the quarter, compared to the consensus estimate of $4.07 billion. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.IQVIA’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same period in the previous year, the business earned $2.84 earnings per share. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. As a group, equities analysts anticipate that IQVIA will post 10.84 EPS for the current fiscal year.

Insider Activity at IQVIA

In related news, insider Eric Sherbet sold 4,000 shares of the company’s stock in a transaction on Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total value of $878,800.00. Following the completion of the transaction, the insider directly owned 27,108 shares in the company, valued at approximately $5,955,627.60. This represents a 12.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 1.60% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Verdence Capital Advisors LLC purchased a new position in shares of IQVIA in the 2nd quarter worth about $3,612,000. Amundi increased its position in IQVIA by 46.3% during the 2nd quarter. Amundi now owns 1,279,817 shares of the medical research company’s stock worth $210,722,000 after purchasing an additional 405,250 shares in the last quarter. Diversified Trust Co raised its holdings in IQVIA by 57.2% in the third quarter. Diversified Trust Co now owns 42,579 shares of the medical research company’s stock valued at $8,087,000 after buying an additional 15,487 shares during the period. Act Two Investors LLC acquired a new position in IQVIA during the second quarter valued at approximately $26,528,000. Finally, Oregon Public Employees Retirement Fund grew its stake in IQVIA by 37.1% during the third quarter. Oregon Public Employees Retirement Fund now owns 19,463 shares of the medical research company’s stock worth $3,697,000 after buying an additional 5,271 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.